SCHEMBL30540486

SCHEMBL30540486

CCOC(=O)c1c(C#N)c(O)nc2c1CCC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.55
ALDH1A1 P00352 8/20 0.55
HSD17B10 Q99714 5/20 0.55
HPGD P15428 5/20 0.55
GAA P10253 4/20 0.55
CASP1 P29466 2/20 0.55
CASP7 P55210 2/20 0.55
MAPK10 P53779 1/20 0.52
MAPT P10636 4/20 0.52
POLB P06746 3/20 0.52
ALOX15 P16050 2/20 0.48
MAPK1 P28482 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
KMT2A Q03164 3/20 0.46
TSHR P16473 2/20 0.46
PKM P14618 2/20 0.45
L3MBTL1 Q9Y468 5/20 0.42
LMNA P02545 2/20 0.42
ACHE P22303 5/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25349781 1.00 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL4677981 0.97 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL3468836 0.80 LMNA (0.50) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL30540586 0.77 MAPT (0.44) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL25349808 0.77 MAPT (0.44) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL30540660 0.77 MAPT (0.44) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL31115365 0.77 MAPT (0.44) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL30076558 0.75 MAPT (0.45) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL20338270 0.75 MAPT (0.45) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL22312018 0.74 KDM4E (0.46) KDM4EALDH1A1HSD17B10HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-05-22 US disclosed
EP-4476219-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene, Ltd. (KY) 2024-12-18 EP disclosed
WO-2023151642-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 WO disclosed
WO-2023151636-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH NFATC1, GZMB, IFNG KDM4E 996/4885ALDH1A1 1242/4885HSD17B10 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.